Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

Inclusion Criteria: * Patients with histological confirmation of non-small-cell lung carcinoma. * Complete surgical resection of the disease. * Tumoral tissue available for molecular analysis. * N1 (stage II) or N2 (stage IIIA) lymph node involvement in the study of the operative piece. * Men or women age 18 years or older. * Patients with a performance status of 2 or less according to the ECOG classification. * Patients with the following laboratory results: ANC \< 1500/L, Hb \< 10 g/dL, platelets \<100,000/L, bilirubin \< 1.0 mg/dL, AST and ALT \< 1.5 upper limit of normality, creatinine clearance \< 60 mL/min. * Complete recovery from surgery within 6 weeks. * Patients who have given written informed consent before initiating any specific study screening procedure. Exclusion Criteria: * Patients who have received previously chemotherapy or radiotherapy for the study disease. * Impossibility of complying with chemotherapy treatment due to cultural or geographic circumstances. * Patients with active infection, heart disease, or any other serious disease, in the judgment of the investigator. * Women who are pregnant or in the period of lactation. * Patients with a previous diagnosis of malignant disease in the last five years except for carcinoma in situ of the uterine cervix or skin cancer other than melanoma. * Patients under treatment with investigational agents.